Logo do repositório
 
Publicação

Molecular signatures of xenograft colorectal cancer in mice treated with topotecan: A mass spectrometry-based study

2025-05-14Artigo científico Acesso aberto
Ver registo simples
datacite.subject.fosCiências Naturais::Ciências Biológicas
dc.contributor.authorHagyousif, Yousra A.
dc.contributor.authorZenati, Ruba A.
dc.contributor.authorSoares, Nelson C.
dc.contributor.authorAl-Hroub, Hamza M.
dc.contributor.authorKhan, Farman Matloob
dc.contributor.authorQaisar, Rizwan
dc.contributor.authorHamoudi, Rifat
dc.contributor.authorEl-Awady, Raafat
dc.contributor.authorAbuhelwa, Ahmad Y.
dc.contributor.authorRamadan, Wafaa
dc.contributor.authorEl-Huneidi, Waseem
dc.contributor.authorAbu-Gharbieh, Eman
dc.contributor.authorAlzoubi, Karem H.
dc.contributor.authorBustanji, Yasser
dc.contributor.authorSemreen, Mohammad H.
dc.date.accessioned2026-01-19T14:18:42Z
dc.date.available2026-01-19T14:18:42Z
dc.date.issued2025-05-14
dc.description.abstractBackground: Colorectal cancer (CRC) is one of the most common cancers worldwide, yet it continues to have a low survival rate, largely due to the lack of effective treatments. Metabolomics offers new insight into disease diagnosis and biomarkers discovery. The aim of the study is to identify serum biomarkers in a CRC xenograft mouse model treated with topotecan using advanced metabolomics techniques to enhance our understanding and management of the disease. Methods: The therapeutic potentials of the anticancer drug topotecan on metabolomic alterations in CRC were explored using the UHPLC-ESI-QTOF-MS platform. A comprehensive metabolomic analysis was conducted to compare four different animal groups: HCT-116 CRC xenograft mice treated with topotecan (treated group), vehicle-control HCT-116 xenograft mice (untreated CRC xenograft mice), positive controls (healthy mice injected with topotecan), and negative controls (healthy mice). Results: The study identified 53 altered metabolites across all four groups (p-value < 0.05). Independent T-test revealed that 15 metabolites were statistically significant among vehicle controls and negative controls. Additionally, 20 metabolites showed significant differences between the potential responders to topotecan and the vehicle controls. Moreover, only one metabolite was statistically significant between the positive and negative controls. Conclusion: The findings provide a detailed characterization of metabolic alterations associated with topotecan treatment in CRC. These insights contribute to a better understanding of the drug's mechanism of action, which may help predict CRC patients' response to topotecan and guide the development of personalized therapeutic strategies.eng
dc.description.sponsorshipThis study was financially supported by the University of Sharjah (competitive grant number 2201110155 and targeted grant number 24011101105.
dc.identifier.citationToxicol Rep. 2025 May 14:14:102045. doi: 10.1016/j.toxrep.2025.102045. eCollection 2025 Jun
dc.identifier.doi10.1016/j.toxrep.2025.102045
dc.identifier.eissn2214-7500
dc.identifier.pmid40496508
dc.identifier.urihttp://hdl.handle.net/10400.18/10714
dc.language.isoeng
dc.peerreviewedyes
dc.publisherElsevier
dc.relation.hasversionhttps://www.sciencedirect.com/science/article/pii/S2214750025001635?via%3Dihub
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectColorectal Cancer
dc.subjectLC-MS/MS-QTOF
dc.subjectMetabolomics
dc.subjectTopotecan
dc.subjectGenómica Funcional e Estrutural
dc.titleMolecular signatures of xenograft colorectal cancer in mice treated with topotecan: A mass spectrometry-based studyeng
dc.typejournal article
dcterms.referenceshttps://ars.els-cdn.com/content/image/1-s2.0-S2214750025001635-mmc1.docx
dcterms.referenceshttps://ars.els-cdn.com/content/image/1-s2.0-S2214750025001635-mmc2.pdf
dspace.entity.typePublication
oaire.citation.startPage102045
oaire.citation.titleToxicology Reports
oaire.citation.volume14
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85

Ficheiros

Principais
A mostrar 1 - 1 de 1
Miniatura
Nome:
2025, Soares, Molecular signatures of xenograft colorectal cancer in mice treated with topotecan_A mass spectrometry-based study.pdf
Tamanho:
5.35 MB
Formato:
Adobe Portable Document Format
Ver/Abrir
Licença
A mostrar 1 - 1 de 1
Miniatura indisponível
Nome:
license.txt
Tamanho:
4.03 KB
Formato:
Item-specific license agreed upon to submission
Descrição:
Ver/Abrir

Coleções

DGH - Artigos em revistas internacionais
INSA - Artigos em revistas internacionais